GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+29.98%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$234M
AUM Growth
+$234M
(-4.4%)
Cap. Flow
-$45M
Cap. Flow
% of AUM
-19.2%
Top 10 Holdings %
Top 10 Hldgs %
57.93%
Holding
46
New
9
Increased
6
Reduced
20
Closed
9
Top Buys
| 1 |
Invesco QQQ Trust
QQQ
|
$13.3M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$10.9M |
| 3 |
Iovance Biotherapeutics
IOVA
|
$8.31M |
| 4 |
Akero Therapeutics
AKRO
|
$4.66M |
| 5 |
Ascendis Pharma
ASND
|
$4.27M |
Top Sells
| 1 |
Relmada Therapeutics
RLMD
|
$15.7M |
| 2 |
Viridian Therapeutics
VRDN
|
$10.8M |
| 3 |
Vaxcyte
PCVX
|
$9.59M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$8.55M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$7.39M |
Sector Composition
| 1 | Healthcare | 94.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RETA
1
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $19M | 8.11% | 500,000 -225,000 | -31% | -$8.55M |
|
2
Axsome Therapeutics
AXSM
$6.05B
| $18.1M | 7.74% | 235,000 -65,000 | -22% | -$5.01M |
|
|
3
Ascendis Pharma
ASND
$11.8B
| $15.9M | 6.78% | 130,000 +35,000 | +37% | +$4.27M |
|
4
Apellis Pharmaceuticals
APLS
$3.48B
| $15.5M | 6.62% | 300,000 +25,000 | +9% | +$1.29M |
|
|
5
Invesco QQQ Trust
QQQ
$364B
| $13.3M | 5.68% | +50,000 | New | +$13.3M |
|
|
6
Amylyx Pharmaceuticals
AMLX
$836M
| $12.9M | 5.52% | 350,000 -200,000 | -36% | -$7.39M |
|
|
CTIC
7
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $11.1M | 4.75% | 1,850,000 -150,000 | -8% | -$902K |
|
|
SGEN
8
DELISTED
Seagen Inc. Common Stock
SGEN
| $10.9M | 4.66% | +85,000 | New | +$10.9M |
|
|
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.64M | 4.11% | 450,000 -13,700 | -3% | -$293K |
|
10
Cogent Biosciences
COGT
$1.69B
| $9.25M | 3.95% | 800,000 +200,000 | +33% | +$2.31M |
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.06M | 3.87% | 200,000 +25,000 | +14% | +$1.13M |
|
|
12
Iovance Biotherapeutics
IOVA
$807M
| $8.31M | 3.55% | +1,300,000 | New | +$8.31M |
|
|
KRTX
13
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $7.86M | 3.36% | 40,000 +10,000 | +33% | +$1.97M |
|
|
14
Vaxcyte
PCVX
$4B
| $7.67M | 3.28% | 160,000 -200,000 | -56% | -$9.59M |
|
15
Sarepta Therapeutics
SRPT
$1.78B
| $7.13M | 3.04% | 55,000 -55,000 | -50% | -$7.13M |
|
16
Astria Therapeutics
ATXS
$349M
| $6.7M | 2.86% | 450,000 -50,000 | -10% | -$745K |
|
17
Madrigal Pharmaceuticals
MDGL
$9.76B
| $5.81M | 2.48% | 20,000 -5,000 | -20% | -$1.45M |
|
|
RVNC
18
DELISTED
Revance Therapeutics, Inc.
RVNC
| $5.54M | 2.36% | 300,000 -90,000 | -23% | -$1.66M |
|
|
19
Viridian Therapeutics
VRDN
$1.5B
| $4.82M | 2.06% | 165,000 -370,000 | -69% | -$10.8M |
|
|
20
Akero Therapeutics
AKRO
$3.74B
| $4.66M | 1.99% | +85,000 | New | +$4.66M |
|
|
PRVB
21
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $4.23M | 1.81% | +400,000 | New | +$4.23M |
|
|
JBIO
22
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $3.96M | 1.69% | 135,000 -15,000 | -10% | -$440K |
|
23
Syndax Pharmaceuticals
SNDX
$1.41B
| $3.82M | 1.63% | 150,000 -50,000 | -25% | -$1.27M |
|
24
Viking Therapeutics
VKTX
$3.04B
| $2.82M | 1.2% | +300,000 | New | +$2.82M |
|
25
BioCryst Pharmaceuticals
BCRX
$1.74B
| $2.58M | 1.1% | 225,000 -300,000 | -57% | -$3.44M |
|